Japan Tobacco Inc. announces the appointment of Takehiko Tsutsui as President of Tobacco Business effective from January 1, 2026. Adam Vilalta is appointed as Senior Vice President, Marketing, Tobacco Business, Japan effective from January 1, 2026. Hisashi Shimobayashi will assume the role of Senior Vice President, Chief Technology & Information Security Officer effective from January 1, 2026.
Koji Shimayoshi will assume the role of Executive Vice President, Corporate Governance, Compliance, Corporate Strategy, Sustainability, People & Culture, Information Technology, Legal, Operation Review & Business Assurance and Food Business effective from December 1, 2025. Yukiko Uchida is a candidate for appointment as new Member of the Board effective from March 25, 2026. Yukiko Uchida is Director (Professor) of Kyoto University Institute for the Future of Human Society.
Shigeaki Okamoto will assume the role of Chairperson of the Board effective from March 25, 2026. Masamichi Terabatake will assume a new position as Member of the Board without the right to represent the Company as of January 1, 2026, and will become Deputy Chairperson of the Board subject to ratification at the 41st Annual General Meeting of Shareholders, scheduled for March 25, 2026, and approval at the Company?s Board of Directors? meeting, scheduled subsequently.
Mutsuo Iwai will resign as Chairperson of the Board upon the conclusion of the 41st Annual General Meeting of Shareholders, scheduled for March 25, 2026. Yukiko Nagashima will resign as Member of the Board upon the conclusion of the 41st Annual General Meeting of Shareholders, scheduled for March 25, 2026. Igor Dzaja will resign as Senior Vice President, Marketing, Tobacco Business, Japan as of December 31, 2025 and is scheduled to assume the position of General Manager, Italy at JT International S.A. Takayuki Yamaguchi will resign as Senior Vice President, President, Pharmaceutical Business as of November 30, 2025.
Makoto Kakutani will resign as Senior Vice President, Head of Central Pharmaceutical Research Institute, Pharmaceutical Business as of November 30, 2025.
